文档介绍:实用癌症杂志 年 月第 卷第 期
2022 4 37 4 The Practical Journal of Cancer,April 2022,Vol 37,N ' , ,458000
Abstract Objective
【 】 To compare the efficacy and safety of bevacizumab and apatinib in the treatment of recurrent cer⁃
Methods
vical cancer. 46 patients with recurrent cervical cancer were randomly divided into bevacizumab group and apatinib
group (23 cases each). On the chemotherapy regimen of paclitaxel + cisplatin,bevacizumab and apatinib were given respective⁃
Results
ly. The efficacy and safety of the 2 methods were compared. There was no significant difference in the total effective rate
P
between bevacizumab group and apatinib group (69. 57% vs 82. 61% ) ( < 0. 05). Before treatment,there was no significant
P
difference in the positive rates of survivin,PTEN,VEGF and CD105 between the 2 groups ( < 0. 05);After treatment,the posi⁃
P
tive rates of four indexes in apatinib group were significantly lower than those before treatment ( < 0. 05)